Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 252.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,826 shares of the company’s stock after acquiring an additional 13,481 shares during the quarter. BNP Paribas Financial Markets’ holdings in Aquestive Therapeutics were worth $94,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $135,000. Charles Schwab Investment Management Inc. lifted its position in Aquestive Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after buying an additional 9,268 shares in the last quarter. Intech Investment Management LLC purchased a new position in Aquestive Therapeutics during the third quarter worth approximately $90,000. GSA Capital Partners LLP boosted its stake in Aquestive Therapeutics by 525.5% during the third quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock worth $683,000 after buying an additional 115,223 shares during the last quarter. Finally, Chartwell Investment Partners LLC purchased a new stake in Aquestive Therapeutics in the 3rd quarter valued at $535,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $3.46 on Thursday. The stock has a market capitalization of $315.48 million, a P/E ratio of -7.69 and a beta of 2.62. The firm’s 50-day moving average is $4.79 and its two-hundred day moving average is $4.07. Aquestive Therapeutics, Inc. has a 12 month low of $1.84 and a 12 month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the prior year, the company posted ($0.03) EPS. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a report on Tuesday. They set an “overweight” rating and a $17.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Leerink Partners boosted their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.